| Literature DB >> 32110175 |
Abeer Alnamankany1, Paul Ashley2.
Abstract
OBJECTIVES: This systematic review aimed to determine the improvement in quality of the reporting of randomized clinical trials (RCTs) in paediatric dentistry. The quality of reporting during the period 2014-2015 was compared with the quality of reporting during 1985-2006.Entities:
Keywords: Paediatric dentistry; Published articles; RCTs; Reporting; Scientific quality
Year: 2020 PMID: 32110175 PMCID: PMC7033395 DOI: 10.1016/j.jtumed.2019.12.006
Source DB: PubMed Journal: J Taibah Univ Med Sci ISSN: 1658-3612
Comparison of compliance of articles against the CONSORT checklist.
| Article Section and Topic | Item | The percentage of reporting (1985–2006) | The percentage of reporting (2014–2015) |
|---|---|---|---|
| Title and abstract | 1 | 71 | 92.5 |
| Background | 2 | 98.8 | 100 |
| Participants | 3 | 90.2 | 89.5 |
| 4 | 79.2 | 95 | |
| Interventions | 5 | 96.0 | 100 |
| Objectives | 6 | 90.2 | 90 |
| Outcomes | 7 | 87.3 | 91.4 |
| 8 | 38.7 | 47.5 | |
| Sample size | 9 | 4.6 | 55 |
| 10 | 0.6 | 10 | |
| Randomisation generation | 11 | 28 | 60 |
| 12 | 5.8 | 15 | |
| Randomisation concealment | 13 | 5.2 | 40 |
| Randomisation implementation | 14 | 5.8 | 40 |
| 15 | 6.4 | 37.5 | |
| 16 | 9.2 | 42.5 | |
| Blinding | 17 | 34 | 40 |
| 18 | 27.7 | 37.5 | |
| 19 | 58 | 58.5 | |
| 20 | 11.6 | 15 | |
| Statistic | 21 | 83.8 | 92.5 |
| 22 | 25.4 | 2.5 | |
| Participant flow | 23 | 45.1 | 52.5 |
| 24 | 13.9 | 17.5 | |
| Recruitment | 25 | 32.9 | 55 |
| Baseline data | 26 | 60.1 | 77.5 |
| Analysis | 27 | 61.3 | 87.5 |
| 28 | 1.2 | 20 | |
| Outcomes | 29 | 57.2 | 62.5 |
| Ancillary analysis | 30 | 21.4 | 2.5 |
| Adverse events | 31 | 57.8 | 35 |
| Discussion | 32 | 97.1 | 98.5 |
| Generalisability | 33 | 98.3 | 98.8 |
| Overall evidence | 34 | 96.5 | 97 |
Figure 1The CONSORT flowchart of articles throughout the study.
PRISMA checklist.
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g. Web address) and, if available, provide registration information including registration number. | N/A |
| Eligibility criteria | 6 | Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g. years considered, language, publication status) used as criteria for eligibility, giving rationale. | 5 |
| Information sources | 7 | Describe all information sources in the search (e.g. databases with dates of coverage, contact with study authors to identify additional studies) and date last searched. | 5 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it can be repeated. | 5 |
| Study selection | 9 | State the process for selecting studies (i.e. screening, eligibility, included in systematic review and, if applicable, included in the meta-analysis). | 5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g. piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 |
| Data items | 11 | List and define all variables for which data were ought (e.g. PICOS, funding sources) and any assumptions and simplifications made. | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level) and how this information is to be used in any data synthesis. | 6 |
| Summary measures | 13 | State the principal summary measures (e.g. risk ratio, difference in means). | N/A (the study was not a meta-analysis) |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g. I39 | N/A (the study was not a meta-analysis) |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. publication bias, selective reporting within studies). | N/A (the study was not a meta-analysis) |
| Additional analyses | 16 | Describe methods of additional analyses if done (e.g. sensitivity or subgroup analyses, meta-regression), indicating which were pre-specified. | N/A (the study was not a meta-analysis) |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 7,15 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g. study size, PICOS, follow-up period) and provide citations. | The number of articles included was high, citations are available on request. |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | N/A (the study was not a meta-analysis) |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present for each study: (a) simple summary data for each intervention group, and (b) effect estimates and confidence intervals (ideally with a forest plot). | 7 |
| Synthesis of results | 21 | Present results of each completed meta-analysis, including confidence intervals and measures of consistency. | N/A (the study was not a meta-analysis) |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see item 15). | N/A (the study was not a meta-analysis) |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-regression [see item 16]). | N/A (the study was not a meta-analysis) |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g. healthcare providers, users, and policymakers). | 8,9 |
| Limitations | 25 | Discuss limitations at study and outcome levels (e.g. risk of bias), and at review level (e.g. incomplete retrieval of identified research, reporting bias). | 10 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence and the implications for future research. | 10,11 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g. supply of data); the role of funders for the systematic review. | 11 |